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Nonenzymatic glycation of tissue and plasma
proteins may stimulate the production of oxi-
dant and carbonyl stress in diabetes. The aim
of this study was to evaluate the effects of
aminoguanidine (AG) on lipid peroxidation,
protein oxidation and nitric oxide (NO) release
in diabetic rat kidneys. After induction of dia-
betes with streptozotocin, female Wistar rats
were divided into 2 groups. Group DAG (n=9)
rats were given AG hydrogen carbonate (1 g/L)
in drinking water and group D (n=8) was dia-
betic control rats given only tap water. Group
H (n=8) was followed as healthy controls. At
the end of an 8 week period, NO release, lipid
and protein oxidation were determined in kid-
ney tissues. NO release was significantly lower
in diabetic rats compared with healthy controls
(p<0.05). Lipid peroxidation was significantly
high in group D (3.9 ± 0.3 nmol MDA/g tissue)
compared with the group DAG (2.6 ± 0.1 nmol
MDA/g tissue, p<0.01) and group H (2.4 ± 0.2
nmol MDA/g tissue). Protein oxidation was
significantly higher in diabetics than healthy
controls (563.8 ± 23.9, 655.8 ± 7.2 , 431.5 ±
8.8 mmol carbonyl / g tissue for group DAG, D
and H, respectively, p< 0.05). A positive corre-
lation between albuminuria and thiobarbituric
acid reactive substance (TBARS) levels (r=
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1560-4284/02 $12.00 + .000.54,p<0.005) and carbonyl content (r=0.70,
p<0.0005) in kidney homogenate were
observed. 
Although AG treatment had no effect on NO
release, it significantly decreased lipid peroxi-
dation in diabetic rat cortices. Consequently
increased lipid peroxidation -as well as- protein
oxidation could be involved in the pathogenesis
of diabetic albuminuria.
INTRODUCTION
Nonenzymatic glycation of long lived struc-
tural proteins is one of the mechanisms that is
involved in the pathogenesis of diabetic
nephropathy [1-4]. Glycation of tissue and
plasma proteins may stimulate the production
of oxidant and carbonyl stress in diabetes [5,6].
Increased lipid and protein oxidation are
thought to trigger diabetic tissue damage [7,8].
Oxidized lipids may in turn stimulate oxidative
reactions of sugars, enhancing damage to both
lipids and proteins [7-9].
Aminoguanidine, (AG) an inhibitor of
advanced glycation, was shown to prevent lipid
peroxidation in human plasma and red blood
cell membranes [10] as well as rat tissues [11].
It is also known to be a selective inhibitor of
inducible nitric oxide synthase [12]. 
Increased glucose and free fatty acids may
stimulate endothelial cells and macrophages to
secrete nitric oxide (NO) and super oxide
which is increased peroxynitrite formation in
diabetic milieu [13]. It is not clear whether inhi-
bition of NO production by AG influences lipid
peroxidation in diabetic tissues.
Carbonyl groups are the end products of
protein oxidation. Their levels in tissues and
plasma serve as relatively stable markers of
oxidative damage [14,15]. Reactive carbonyl
compounds and residual carbonyl groups of
modified proteins react covalently with matrix
tissue proteins and alter their structure and
function [9,16]. Carbonyl modification of pro-
teins by auto oxidation of sugars is thought to
be associated with kidney damage in diabetes
[17]. Cross talk between oxidative stress, pro-
tein oxidation and NO metabolism seems to be
complex in diabetic milieu and the effects of
advanced glycation inhibition in this setting
remains to be determined. 
The aim of this study was to evaluate the
effects of aminoguanidine on NO release, lipid
and protein oxidation in diabetic kidney tis-
sues. The relationship between urinary albumin
excretion and lipid peroxidation , protein oxi-
dation were also evaluated.
MATERIALS AND METHODS
Twenty-five ten-week-old female Wistar rats
were used in the study. Seventeen rats were
made diabetic by i.p injection of 65 mg/kg
Streptozotocin in sodium citrate buffer pH 4.5.
Eight rats receiving an equivalent amount of
buffer served as healthy controls (Group H) .
One week after induction of diabetes, 9 rats
(Group DAG) were given aminoguanidine
bicarbonate (Sigma MO,USA) ad libitum in
drinking water at a concentration of 1 g/L [18].
Eight diabetic rats were followed up as diabet-
ic controls (Group D) and given only tap water.
None of the groups received hypoglycemic
agents. During the study, rats were kept in tem-
perature (25oC) and light-(12h light,12h dark)
controlled rooms and fed a standard 20% pro-
tein-containing rat chow. All experiments were
conducted in accordance with internationally
accepted principles for the care and use of lab-
oratory animals and were approved by the
committee for animal research of Marmara
University Medical School.
At the end of the 8-week period, 24-hour
urine samples were collected in metabolic
cages. Blood samples were collected by cardiac
puncture while rats were kept under ether anes-
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thesia. Their kidneys were rapidly dissected and
exposed to liquid nitrogen and immediately
stored at -70 0C until use.
Determination of plasma glucose and creati-
nine: Plasma glucose was measured with a col-
orimetric method using glucose oxidase
(Boehringer Mannheim, Germany) for Hitachi
705 autoanalyser. 
Determination of urinary albumin excretion:
Urinary albumin excretion was determined by
using a Titan gel electrophoresis kit from
Helena Laboratories (Sunderland, UK).
Tissue preparation: Rat kidney cortices were
dissected (40-50mg) and put into scintillation
vials for NO release assay. Rat kidney cortices
were also homogenized (%5, w/v) in Hank’s
buffer (pH 7.2) for oxidative stress parameters
and sulfhydryl group assays.
Determination of NO release: NO release
was detected by using luminol H2O2 chemilu-
minescence with minimal modifications
described by Kikuchi et al [19]. Rat kidney cor-
tices were placed in glass scintillation vials con-
taining 3 ml of Hank’s buffer +HEPES.
Chemiluminescence probe (18 µM luminol,150
mm desferrioxamine, 10 mM H2O2, 2mM
potassium carbonate) was added and chemilu-
minescence measurements were recorded for 5
min at 30 sec intervals. Area under the curve
(AUC) was calculated for each experiment
(cpm/mg tissue for 5 min).
Determination of lipid peroxidation: Kidney
cortex homogenates (5%,w/v) were mixed with
an equal volume of ice cold 10%
trichloroacetic acid (TCA). After centrifuga-
tion, a volume of the supernatant was added to
an equal volume of 0.67 % thiobarbituric acid
(TBA) and the mixture was kept in a boiling
water bath for 15 min. Samples were cooled to
room temperature and absorbance at 532 nm
were recorded. The results were expressed as
MDA equivalents using a molar extinction
coefficient of 1.56 x105M-1 cm-1 [20].
Determination of tissue protein oxidation:
Carbonyl contents of proteins were deter-
mined by a modification of the procedure
described by Levine et al [21]. Results were
expressed as nanomoles per gram tissue using a
molar extinction coefficient of 22 000 M-1 cm-1.
Statistical analyses were performed with an
IBM compatible PC using Instat III program.
Kruskall Wallis ANOVA, Mann Whitney U
tests were used for comparisons of the groups
as appropriate. Spearman Rank test was used
for the correlation analysis. Results are
expressed as mean±SEM.
RESULTS
Table 1 lists blood glucose and urinary albu-
min excretion (UAE) rates in all study groups.
Diabetic rats had significantly elevated plasma
glucose and urinary albumin levels compared
to non-diabetic rats. Aminoguanidine therapy
retarded the increase in urinary albumin excre-
tion at 8 weeks to levels approaching but still
higher than those of healthy control rats (D vs
DAG p<0.001). Plasma glucose levels were not
affected by aminoguanidine treatment in dia-
betic rats.
Lipid peroxidation, protein oxidation and
NO release from rat kidney cortices are shown
in Table 2. TBARS content of renal cortices in
non-treated diabetic rats was significantly ele-
vated compared to healthy (p<0.05) and AG
treated diabetic rats (p<0.05). TBARS were
higher in the renal cortices of the non-treated
diabetic group while AG treated diabetic rats
had similar values with healthy controls.
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measured only in 7 rats from the DAG group
and 6 rats from each of the other groups.
Diabetic rats had higher levels of protein oxi-
dation than healthy rats (p<0.05). AG tended
to decrease renal tissue protein oxidation levels
in diabetic rats but the difference was not sta-
tistically significant compared with diabetic
controls.
Urinary albumin excretion showed a signifi-
cant positive correlation with renal cortex
TBARS levels (r=0.54, p<0.005) and carbonyl
content (r=0.70, p<0.0005) (Figure 1). There
was no significant correlation between TBARS
and protein oxidation levels of kidney cortices.
Non-treated diabetic rats had lower levels of
NO release from kidney, compared to healthy
control rat tissues and AG treatment had no
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FIGURE 1 
Correlation analysis of urinary albumin excretion with TBARS and carbonyl content of renal cortex tissues of all study groups.
TABLE 1  Blood glucose and urinary albumin excretion in all study groups 
Group H Group D Group DAG
Glucose (mg/dl) 86.2±17* 466.6±125 389.6±128.1
UAE (µg/d) 187.5±99.4 1414.7±769** 392.7±134.9
* p <0.001 vs other groups ,** p <0.001 vs H, p <0.05 vs DAG
UAE: Urinary albumin excretion H: Healthy control group, 
D: Diabetic control group, DAG: Aminoguanidine treated diabetic groupsignificant effect on NO release.
DISCUSSION
In this study lipid peroxidation as measured
by TBARS, which is an index of malondialde-
hyde production, was found to be elevated in
renal tissues of non-treated diabetic rats com-
pared with healthy controls. This is in accor-
dance with the findings of others who have
shown that lipid peroxidation is increased in
diabetic rats [10,22,23].
Aminoguanidine treated diabetic rats had
lower lipid peroxidation in kidney cortex
homogenates than non-treated diabetic rats.
These results support those of Kedziora-
Karnotowska et al. [10] who reported that
aminoguanidine treatment attenuated the
increase in MDA content and diminished activ-
ities of key antioxidant enzymes in kidney
homogenates of STZ- diabetic rats. 
A positive correlation between urinary albu-
min excretion and renal tissue MDA content
might be indicating that lipid peroxidation in
renal tissues could have an influence on the
progression of albuminuria in diabetic rats.
Reactive oxygen species mediated reactions
lead to the formation of protein carbonyl deriv-
atives, which serves as a marker of protein
damage. Reactive carbonyl compounds have
been found to be present in diabetic glomerular
lesions [24]. Reactive carbonyl compounds is
the result of oxidative stress and could be an
active contributor to pathogenesis of diabetic
complications. Brownlee et al [25] had demon-
strated that aminoguanidine inhibits the forma-
tion of reactive carbonyl compounds in arterial
wall. In this study we observed increased pro-
tein oxidation in diabetic rat kidney tissues
compared to healthy controls. Carbonyl con-
tent of kidney tissue homogenates showed a
significant positive correlation with urinary
albumin excretion in all study groups. This
result suggests that protein oxidation might be
taking a part in the pathogenesis of diabetic
nephropathy. But our data failed to show a sig-
nificant effect of aminoguanidine on protein
oxidation in diabetic rats which could be due to
small study groups.
Defective nitric oxide production is associat-
ed with diabetic nephropathy. Several studies
have demonstrated that pathophysiologic and
morphologic changes in diabetic nephropathy
are mediated by either increase or decrease in
renal NO production or activity [26,27].
H2O2 induced NO release was found to be
decreased in diabetic rat kidneys in our study.
This finding is in accordance with the results of
Craven et al. [28] who measured basal NO pro-
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TABLE 2  Nitric oxide release, lipid peroxidation and protein oxidation measurements in 
rat kidney tissues
Group H Group D Group DAG
NO Release 2440310 ± 48921 * 497703 ± 89525 461844 ±174330
fmol.min-1
(g of kidney weight)-1
TBARS 2.45 ±0.7 3.9 ±1.0 † 2.6 ±0.5
(nmol MDA / g tissue) 
Protein oxidation  431.4 ±8.8 ‡ 655.8 ±75.2 563.8 ±23.9
(nmol carbonyl / g tissue)
* p <0.05 vs other groups † p <0.05 vs H and group DAG, ‡ p<0.05 vs other groups
TBARS: Thiobarbituric acid reactive substances, H: Healthy control group, 
D: Diabetic control group, DAG: Aminoguanidine treated diabetic groupduction with an NO electrode in isolated
glomeruli from diabetic rats and found that
NO production was markedly reduced in
glomeruli from two month diabetic rats. An
advanced glycation inhibitor, aminoguanidine,
which is also a nitric oxide synthase inhibitor,
had no significant effect on H2O2 induced NO
release from diabetic rat kidneys in our study.
NO release showed no correlation between
lipid peroxidation, protein oxidation and albu-
minuria. These results are in accordance with
the results of Soulis et al [12], who demon-
strated that aminoguanidine had no effect on
inducible nitric oxide synthesis while it pre-
vented increases in albuminuria. They conclude
that the effect of aminoguanidine has been
mediated predominantly by decreased AGE
formation rather than via NOS inhibition [12].
Our data confirm the favorable effects of
aminoguanidine in preventing the increase in
albuminuria and lowering lipid peroxidation
while no statistically significant effect on NO
release in diabetic rats. Aminoguanidine treat-
ment tended to lower renal cortex carbonyl
content. Since the carbonyl content of kidney
tissues was positively correlated with urinary
albumin excretion in diabetic rats; protein oxi-
dation could be one of the causes of albumin-
uria in diabetes. 
In conclusion, aminoguanidine treatment
reduces albuminuria and lipid peroxidation in
renal cortices of diabetic rats. It may have an
additional beneficial effect as an antioxidant
against lipid and protein oxidation and thereby
diminish diabetic albuminuria.
REFERENCES
1. Lee H.B., Cha M.K., Song K.I., Kim J.H., Lee E.Y., Kim
S.I., Kim J., Yao M.H. (1997) Pathogenic role of advanced
glycosylation end products in diabetic nephropathy,
Kidney Int, 52 (Suppl 60), S60-S65.
2. Makino H., Shikata K., Kaushiro M., Hironaka K.,
Yamasaki Y., Sagimato H., Ota Z., Araki N., Hariuchi S.
(1996). Roles of advanced glycation end-products in the
progression of diabetic nephropathy, Nephrol Dial
Transplant, 11 (Suppl 5), 76-80.
3. Beisswenga P.J., Makita Z., Curphey J., Moore L.L., Jean
S., Brinck-Johnsen T., Bucala R., Vlassara H. (1995).
Formation of immunochemical advanced glycosylation end
products precedes and correlates with early manifestations
of renal and retinal disease in diabetes, Diabetes, 44, 824-
829.
4. Vlassara H., Striker L.J., Teichberg S., Fuh H., Ming Li
Y.M., Steffes M. (1994). Advanced glycation end products
induce glomerular sclerosis and albuminuria in normal
rats, Proc Natl Acad Sci USA, 91, 11704-11708.
5. Laske C., Neumann A., Cunningham A.M, Nichol K.,
Schinzel R., Riederer P., Münch G. (1998). Cytotoxicity of
advanced glycation end products is mediated by oxidative
stress, J Neurol Transm 105, 1005-1015.
6. Suzuki D. and Miyata T. (1999). Carbonyl stress in the
pathogenesis of diabetic nephropathy, Internal Medicine,
38 (4), 309-314.
7. Chisolm G.M., Irwin K.C., Penn M.S. (1992). Lipoprotein
oxidation and lipoprotein induced cell injury in diabetes,
Diabetes, 41 (suppl 2), 61-66.
8. Baynes J.W. and Thorpe S.R. (1999). Role of oxidative
stress in diabetic complications:a new perspective on an
old paradigm, Diabetes, 48, 1-9.
9. Lyons T.J., Jenkins A.J. (1997). Lipoprotein glycation and
it’s metabolic consequences. Curr Opin Lipidol, 8:3 174-
80.
10. Kedziora-Karnotowska K.Z., Luciak M., Blaszczyk J.
Pawlak W. (1998). Lipid peroxidation and activities of
antioxidant enzymes in erythrocytes of patients with non-
insulin dependent diabetes with or without diabetic
nephropathy, Nephrol Dial Transplant, 13, 2829-2832.
11. Kedzora-Karnotowska K., Luciak M. (1998). Effect of
aminoguanidine on lipid peroxidation and activities of
antioxidant enzymes in the diabetic kidney, Biochem Mol
Biol Int, 46(3), 577-583.
12. Saulis T., Cooper M.E., Sastra S., Thallas V.,
Panagiotopoulos S., Bjerrum O.J., Jerums G. (1997).
Relative contributions of advanced glycation and nitric
oxide synthase inhibition to aminoguanidine mediated
renoprotection in diabetic rats, Diabetologia, 40, 1141-
1151.
13. Traub O. and Van Bibler R. (1995). Role of nitric oxide in
insulin dependent diabetes mellitus- related vascular com-
plications, West J Med, 162, 439-445.
14. Odetti P., Garibaldi S., Nobresco G., Aragno I.,Valentini
S., Traverso N., Marinari U.M. (1999). Levels of carbonyl
groups in plasma proteins of type 2 diabetes mellitus sub-
jects, Acta Diabetol, 36, 179-83.
15. Chevion M., Berenshtein E., Stadtman E.R. (2000).
Human studies related to protein oxidation: protein car-
bonyl content as a marker of damage, Free Radic Res, 33,
suppl 99-108.
16. Mivata T., Sugiyama S., Suzuki D., Inagi R., Kurakowa K.
(1999). Increased carbonyl modification by lipids and car-
bohydrates in diabetic nephropathy, Kidney Int, (Suppl
71), S54-56.
150 YAVUZ, ET AL.
I NTERNATIONAL J OURNAL OF E XPERIMENTAL D IABETES R ESEARCH17. Raj D.S.J., Choudhury D., Welbourne T.C., Levi M.
(2000). Advanced glycation end products: a nephrologist’s
perspective, Am J Kidney Disease, 35, 365-380.
18. Soulis-Liparota T., Cooper M.E., Papazoglou D., Clarke
B., Jerums G. (1991). Retardation by Aminoguanidine of
development of albuminuria, mesengial expansion and tis-
sue fluorescence in streptozotocin-induced diabetic rat,
Diabetes, 40, 1328-1334.
19. Kikuchi K., Nagano T., Haiakawa Hirata Y., Hirote M.
(1993). Real time measurement of nitric oxide produced
ex vivo by luminol-H2O2 chemiluminescence method. J
Biol Chem, 268, 23106-23110.
20. Yalçın A.S., Haklar G., Küçükkaya B., Yüksel M.
Dalaman G. (1998). Chemiluminesence measurements for
the detection of free radical species. In Free Radicals.
Oxidative Stress and Antioxidants edited by T. Ozben pp.
355-390. New York, Plenium Press.
21.  Levine R.L., Garland D., Oliven C.N., Amici A., Climent
I., Lenz A.G., Ahn B.V., Shantiel S., Stadtman E.R. (1990).
Determination of carbonyl content in oxidatively modified
proteins. Methods Enzymol, 186, 464-478.
22. Kakkar R., Kalra J., Mantha S.V., Prasad K. (1995). Lipid
peroxidation and activity of antioxidant enzymes in dia-
betic rats, Moll Cell Biochem, 151 (2),113-119.
23. Brounlich H., Marx F., and Stein G. (1994). Glutathion
status, lipid peroxidation and kidney function in streptozo-
tocin diabetic rats, Exp Toxicol Pathol, 46(2), 143-7.
24. Suzuki D., Miyata T., Saotome N., Horie K., Inagi R.,
Yasuda Y., Uchida K., Izuhara Y., Yagama M., Sakai H.
Kurokawa K. (1999). Immunohistochemical evidence for
an increased oxidative stress and carbonyl modification of
proteins in diabetic glomerular lesions. J Am Soc Nephrol,
10, 822-832.
25. Brownlee M., Vlasara H., Kooney A., Ulrich P., Cerami A.
(1986). Aminoguanidine prevents diabetes-induced arterial
wall protein cross-linking. Science, 232, 1629-1632.
26. Raij L., Baylis C. (1995). Glomerular actions of nitric
oxide. Kidney Int, 48, 20-32.
27. Keynan S., Hirsberg B., Levin-Iaina N., Wexler ID., Dahan
R., Reinhartz E., Ovadia H., Wollman Y., Chernihovskey
T., Iaina A., Raz I. (2000). Renal nitric oxide production
during early phase of experimental diabetes mellitus.
Kidney Int., 58, 740-747.
28. Craven P.A., Struder R.K., DeRubertis F.R. (1995).
Impaired nitric oxide release by glomeruli from diabetic
rats, Metabolism, 44, 695-698.
AMINOGUANIDINE ON LIPID AND PROTEIN OXIDATION 151
I NTERNATIONAL J OURNAL OF E XPERIMENTAL D IABETES R ESEARCH